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ABSTRACT
Introduction: Targeted biological therapies for
psoriasis have resulted in significant benefits,
with therapeutic goals such as clear or almost
clear skin accompanied by improvements in
health-related quality of life (HRQoL). The
objective of this study was to compare the
effects of 52 weeks of treatment with bro-
dalumab or ustekinumab on HRQoL in patients
with moderate-to-severe plaque psoriasis.
Methods: Data were pooled from two ran-
domised controlled phase 3 trials (AMAGINE-2
and -3) which included patients with moderate-
to-severe plaque psoriasis treated with bro-
dalumab 210 mg or ustekinumab 45 or 90 mg
for 52 weeks. HRQoL outcomes were measured
using the Dermatology Life Quality Index
(DLQI) as well as the DLQI-Relevant (DLQI-R)
version which excludes ‘not relevant’ responses.
Results: A total of 929 patients were included,
339 in the brodalumab group and 590 in the
ustekinumab group. A significantly greater
reduction (improvement) in DLQI score from
baseline was observed in the brodalumab group
compared with the ustekinumab group at weeks
4 [least-squares (LS) mean difference - 2.9, 95%
confidence interval [CI] - 3.6 to - 2.2;
p\0.001), 12 (LS mean difference - 0.85, 95%
CI - 1.5 to - 0.2; p = 0.01) and 52 (LS mean
difference - 0.94, 95% CI - 1.6 to - 0.2;
p = 0.009)]. Significantly greater proportions of
patients treated with brodalumab achieved a
DLQI score of 0 at weeks 4 (15.0 vs. 5.4%; p\
0.0001), 12 (37.5 vs. 28.0%; p = 0.0140) and 52
(46.3 vs. 30.3%; p\0.0001), or of B 1 [DLQI (0/
1): 33.9 vs. 15.4%, 59.9 vs. 45.6% and 54.9 vs.
39.8%, respectively; all p \ 0.0001]. Similar
results were observed using the DLQI-R scoring
system. Significantly more patients achieved a C
4 or C 5 improvement in DLQI with bro-
dalumab compared to ustekinumab at weeks 4
and 52. Treatment with brodalumab was asso-
ciated with significantly more patients achiev-
ing a DLQI of 0 compared to ustekinumab for all
domains after 4 and 52 weeks.
Conclusion: Brodalumab was associated with a
significantly greater improvement in HRQoL
compared to ustekinumab in patients with
moderate-to-severe psoriasis.
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Key Summary Points
Both ustekinumab and brodalumab have
been associated with significantly
improved health-related quality of life in
patients with moderate-to-severe
psoriasis, as measured by the Dermatology
Life Quality Index (DLQI). Brodalumab
has also been shown to provide superior
skin clearance to ustekinumab in patients
with moderate-to-severe plaque psoriasis
in randomised controlled trials.
In an analysis of data pooled from two
randomised, controlled, phase 3 trials of
patients with moderate-to-severe plaque
psoriasis, a significantly greater reduction
(improvement) in DLQI score from
baseline was observed with brodalumab
compared to ustekinumab at weeks 4, 12
and 52.
More patients treated with brodalumab
than ustekinumab achieved a DLQI score
of 0 or 0/1.
Brodalumab was associated with a
significantly greater improvement in
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INTRODUCTION
Psoriasis can have a substantial negative impact
on the health-related quality of life (HRQoL) of
patients, affecting emotional well-being and
interfering with daily activities, including home
life, social activity and work functioning. The
use of targeted biological therapies has resulted
in significant improvements in the treatment of
psoriasis with therapeutic goals, such as clear or
almost clear skin, attainable for many patients.
These improvements in clinical efficacy have
been associated with significant benefits in the
self-reported HRQoL of patients [1].
Biological treatments include ustekinumab,
which targets the interleukin (IL)-12/23 path-
way and, more recently, IL-17 inhibitors,
including secukinumab and ixekizumab, which
bind to the IL-17 ligand, and brodalumab,
which binds to the IL-17 receptor A and inhibits
the action of multiple pro-inflammatory IL-17
family cytokines. Both ustekinumab and bro-
dalumab have been associated with signifi-
cantly improved HRQoL in patients with
moderate-to-severe psoriasis, as measured by
the Dermatology Life Quality Index (DLQI)
[2–5]. Previous studies have suggested that IL-17
inhibition with secukinumab or ixekizumab is
associated with greater improvements in skin
clearance and HRQoL than ustekinumab [6–8].
Brodalumab has also been shown to provide
superior skin clearance to ustekinumab in
patients with moderate-to-severe plaque psori-
asis in two 1-year randomised controlled trials
(AMAGINE-2 and AMAGINE-3) [9]. However,
the comparative effects of brodalumab and
ustekinumab on HRQoL from these trials have
not previously been reported.
Here, we report the effects of 1-year of
treatment with brodalumab or ustekinumab on
the HRQoL in patients with moderate-to-severe
plaque psoriasis enrolled in the AMAGINE-2
and AMAGINE-3 phase 3 trials.
METHODS
AMAGINE-2 and AMAGINE-3 were two multi-
centre, randomised, double-blind, placebo-
controlled and active comparator-controlled
phase 3 trials [9]. In both trials, patients were
randomised (2:2:1:1) to brodalumab 210 mg or
140 mg, ustekinumab (45 mg for patients with a
body weight B 100 kg and 90 mg for
patients[100 kg) or placebo. At week 12,
patients originally randomised to brodalumab
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underwent repeat randomisation (2:2:2:1) to
brodalumab 210 mg every 2 weeks, 140 mg
every 2 weeks, 140 mg every 4 weeks or 140 mg
every 8 weeks. Full details of these studies have
been previously reported [9]. The present anal-
ysis was focused on the on-label dosages for
brodalumab so only those patients randomised
to brodalumab 210 mg for the entire 52 weeks
were included.
Patients eligible for enrolment were aged
18–75 years and candidates for biologic therapy
for stable moderate-to-severe plaque psoriasis
(minimum disease duration of 6 months) with a
psoriasis area and severity index (PASI) score of
C 12, a physician’s global assessment (PGA)
score of C 3, and involvement of C 10% of body
surface area. The institutional review board
(IRB) at each participating centre approved the
study protocols (list of IRBs is given in the
Acknowledgements). Both studies were con-
ducted in accordance with the Helsinki Decla-
ration of 1964, and its later amendments and all
relevant regional regulations. All patients pro-
vided written informed consent.
HRQoL was assessed using the DLQI, a ten-
item measure assessing a patient’s self-assess-
ment of their quality of life and problems
associated with dermatological disease. DLQI
total scores range from 0 to 30, with lower
scores indicating better dermatology-specific
quality of life and a score of 0 or 1 both repre-
sentative of no disease effect at all on HRQoL. In
the present study, the DLQI questionnaire was
completed by patients at baseline and every 4
weeks during the 52-week treatment period.
Endpoints included changes in mean DLQI and
changes in the six individual domains (symp-
toms and feelings, daily activities, leisure, work
and school, personal relationships and treat-
ment), percentage of patients achieving DLQI
total scores of 0 and B 1 (0/1) at weeks 12 and
52, patients achieving a C 4- or C 5-point
improvement in DLQI from baseline and area-
under-the-curve (AUC) for DLQI 0/1.
Of the ten items of the DLQI, eight include
‘not relevant’ as a possible response, meaning
patients do not consider that the item is appli-
cable to their lifestyle. In the original DLQI, a
‘not relevant’ response (NRR) is scored as having
no impact on the patient’s HRQoL. High rates of
NNRs have previously been observed among
patients with psoriasis, and concerns have been
raised regarding the potential for NRRs to lead
to a lower DLQI and thus the patient being
categorised as having a higher quality of life
than may be the case [10]. An adjusted scoring
system for the DLQI that is intended to correct
for bias in the NRR option (DLQI-R) has been
proposed [11]. The DLQI-R was also used to
determine proportions of patients achieving
DLQI 0/1 in a post-hoc analysis.
Statistical Analysis
All binary endpoints were analysed and com-
pared between treatments by odds ratios (ORs)
and 95% confidence intervals (CIs) calculated
using a Cochran-Mantel–Haenszel Chi-squared
test stratified by total body weight at baseline
(B or[100 kg), prior biologic use, geographic
region and baseline DLQI score (B or[me-
dian). Missing data for binary endpoints were
accounted for by non-responder imputation
(NRI).
For continuous outcomes, an analysis of
covariance model adjusting for total body
weight at week 12 (B or[ 100 kg), week 12
static PGA (sPGA) response (0, C 1), study and
treatment was used. Last observation carried
forward (LOCF) method was used to impute
missing data.
The full analysis set included all patients
randomly assigned to treatment with at least
one efficacy assessment after randomisation.
All statistical analyses were performed using
SAS version 9.4 or higher (SAS Institute Inc.,
Cary, NC, USA).
RESULTS
A total of 929 patients were included in the
present analysis, 339 in the brodalumab 210 mg
group and 590 in the ustekinumab group.
Baseline demographic and clinical characteris-
tics were similar across both groups (Table 1).
DLQI at baseline was similar in both treatment
groups, with mean [± standard deviation (SD)]
scores of 14.8 ± 7.3 in the brodalumab group
and 14.9 ± 7.3 in the ustekinumab group.
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Mean individual domain scores were also simi-
lar between groups at baseline.
A significantly greater reduction (improve-
ment) in DLQI score from baseline was observed
in the brodalumab group compared with the
ustekinumab group at weeks 4 [mean ± SD -
10.4 ± 7.0 vs. - 7.5 ± 6.3; least-squares (LS)
mean difference - 2.9, 95% CI - 3.6 to - 2.2;
p\0.001], 12 [- 11.7 ± 7.8 vs. - 10.9 ± 7.2;
LS mean difference - 0.85, 95% CI - 1.5 to
- 0.2; p = 0.01] and 52 [- 12.1 ± 8.1 vs. -
11.2 ± 7.7; LS mean difference - 0.94, 95%
CI - 1.6 to - 0.2; p = 0.009].
Significantly greater proportions of patients
treated with brodalumab achieved a DLQI score
of 0 at week 4 compared with ustekinumab-
treated patients (15.0 vs. 5.4%; OR 2.95, 95% CI
1.82–4.79; p\0.0001) and this difference
remained significant at weeks 12 (37.5 vs.
28.0%; OR 1.45, 95% CI 1.08–1.95; p = 0.0140)
and 52 (46.3 vs. 30.3%; OR 2.08, 95% CI
1.55–2.78; p\0.0001]) (Fig. 1a). Similarly,
among patients with a DLQI score[ 1 at base-
line, more patients in the brodalumab group
than ustekinumab group achieved a DLQI score
of 0/1 at weeks 4 (33.9 vs. 15.4%; OR 2.82, 95%
CI 2.01–3.95; p\0.0001), 12 (59.9 vs. 45.6%;
OR 1.74, 95% CI 1.32–2.31; p\ 0.0001) and 52
(54.9% vs. 39.8%; OR 1.90, 95% CI 1.43–2.53;
p\0.0001) (Fig. 1b). The AUC for patients
achieving DLQI 0/1 was significantly higher for
those receiving brodalumab than for those on
ustekinumab (53.1 vs. 39.7%; AUC ratio 1.34;
p\0.0001) (Fig. 2).
An analysis using the adjusted DLQI-R scor-
ing system showed generally similar results for
the proportions of patients achieving DLQI-R
0/1, although there was a slightly lower pro-
portion of patients achieving DLQI-R 0/1 com-
pared to DLQI 0/1 (Fig. 1c). NRRs were most
frequent for the sport (13.5%), working/study-
ing (11.6%) and sexual difficulties (10.1%)
items, with other items having 1.2–3.6% NRRs.
As with the unadjusted DLQI, a significantly
higher proportion of patients achieved DLQI-R
0/1 with brodalumab than ustekinumab at
weeks 4 (30.1 vs. 12.2%; OR 3.00, 95% CI
2.10–4.29; p\0.0001), 12 (55.5 vs. 41.4%; OR





Age, years 44.5 (13.4) 45.1 (13.0)
Male, n (%) 230 (67.8) 404 (68.5)
Weight, kg 90.4 (24.2) 91.0 (22.9)
Race, white, n (%) 308 (90.9) 532 (90.2)
Disease duration, years 17.3 (11.7) 18.6 (12.2)
Body surface area
involvement, %








14.8 (7.3) 14.9 (7.3)
Nail Psoriasis Severity
Index (NAPSI) score
9.3 (3.6) 9.9 (3.6)
Psoriasis Symptom
Inventory (PSI) score
19.1 (7.0) 18.7 (6.9)
Psoriatic arthritis, n (%) 79 (23.3) 110 (18.6)
Systemic treatment-
naı̈ve, n (%)




99 (29.2) 188 (31.9)
Previous biologic
without failure, n (%)
50 (14.8) 95 (16.1)
Previous biologic failure,
n (%)
46 (13.6) 61 (10.3)
All data are presented as the mean with the standard
deviation (SD) in parentheses unless otherwise indicated
cFig. 1 Proportions of patients achieving DLQI score of 0
(a) or 0/1 (b) or a DLQI-R score of 0/1 (c) per visit with
brodalumab or ustekinumab (full analysis set, non-respon-
der imputation). DLQI Dermatology Life Quality Index,
DLQI-R adjusted DLQI correcting for bias in the ‘not
relevant’ response (NRR), Q2W once every 2 weeks
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1.75, 95% CI 1.32–2.32; p\0.0001) and 52
(52.2 vs. 37.8%; OR 1.88, 95% CI 1.41–2.50;
p\0.0001).
Among patients with baseline DLQI C 4,
significantly more achieved a C 4-point
improvement with brodalumab compared with
ustekinumab at week 4 and week 52, although
not at week 12 (Fig. 3). A similar pattern was
seen among patients with baseline DLQI C 5 at
weeks 4 (83.6 vs. 67.7%; OR 2.73, 95% CI
1.87–3.99; p\0.0001), 12 (88.2 vs. 86.4%; OR
1.24, 95% CI 0.80–1.92; p = 0.3384) and 52
(62.8 vs. 48.5%; OR 1.88, 95% CI 1.40–2.54;
p\0.0001).
Treatment with brodalumab was associated
with significantly more patients achieving DLQI
0 compared to ustekinumab for the domains of
symptoms and feelings, daily activities, leisure
Fig. 2 The AUC for DLQI score 0/1 with brodalumab or ustekinumab. AUC = 100% would mean 100% of patients
achieve and maintain DLQI 0/1 from week 0 to week 52 (ideal response). AUC Area-under-the-curve
Fig. 3 Patients achieving an improvement in DLQI of C 4 points with brodalumab and ustekinumab at 4, 12 and 52 weeks
(full analysis set, non-responder imputation). CI Confidence interval, OR odds ratio
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and treatment after 4, 12 and 52 weeks (Fig. 4).
Proportions of patients achieving DLQI 0 were
also significantly higher with brodalumab ver-
sus ustekinumab for work and school and per-
sonal relationships at weeks 4 and 52 but were
not significantly different between groups at
week 12.
DISCUSSION
Psoriasis represents a considerable burden for
patients, often resulting in feelings of embar-
rassment and anxiety and poor self-esteem and
limiting daily, social and work-related activities
[12, 13]. Biological treatments such as bro-
dalumab and ustekinumab have resulted in
significant improvements in outcomes for
patients with moderate-to-severe psoriasis, with
complete or near complete skin clearance now a
realistic treatment goal. However, patients with
psoriasis and their physicians may differ
regarding how much importance they place on
different treatment outcomes [14]. To be clini-
cally meaningful for patients, objective
improvements in symptoms, such as those
reported by PASI, need to be accompanied by
improvements in subjective self-reported
HRQoL measures, including the DLQI.
Several studies have previously reported that
both brodalumab and ustekinumab improve
HRQoL. In a phase II, randomised, placebo-
controlled clinical study of 198 patients with
moderate-to-severe psoriasis, clinically mean-
ingful improvements in DLQI were observed as
early as week 4 following initiation of treatment
Fig. 4 Patients achieving DLQI 0 for individual domains with brodalumab and ustekinumab at 4, 12 and 52 weeks (full
analysis set, non-responder imputation)
Dermatol Ther (Heidelb) (2021) 11:1265–1275 1271
with brodalumab [4]. DLQI scores were signifi-
cantly improved across all domains at week 12.
In a 5-year open-label extension of this study,
treatment with brodalumab resulted in sub-
stantial improvements in HRQoL, with over
two-thirds of patients achieving DLQI 0/1 from
week 12 through to week 264 [15]. Ustek-
inumab has also been associated with signifi-
cant improvements in HRQoL as measured by
the DLQI [2, 3], which have been reported to be
maintained for up to 3 years of treatment [16].
Ustekinumab was also associated with a sus-
tained improvement in DLQI among 489
patients with psoriasis after transitioning from
methotrexate [17]. However, DLQI improve-
ments with ustekinumab have been reported to
be less than those with the IL-17 inhibitors
secukinumab or ixekizumab [7, 8].
In the present study, improvements in
HRQoL were significantly greater with bro-
dalumab than with ustekinumab. Also, mean
DLQI scores were lower, and more patients
achieved a DLQI of 0 or 0/1 with brodalumab at
weeks 4, 12 and 52, indicating a more rapid
improvement in HRQoL with the difference
being maintained over 1 year of treatment.
More patients also achieved a C 4-point
improvement with brodalumab compared with
ustekinumab, which is the recommended min-
imal clinically important difference of the DLQI
[18]. The cumulative benefit of brodalumab
over ustekinumab regarding HRQoL was con-
firmed by the AUC ratio for DLQI 0/1 of 1.34.
Improvements were also seen in each individual
DLQI domain.
Improvement in quality of life tends to be
associated with high skin clearance scores [15].
PASI and DLQI are closely correlated, with a
substantial improvement in clinical efficacy
associated with improved HRQoL in patients
with moderate-to-severe psoriasis, and a signif-
icant difference in DLQI score of 0/1 between
PASI 75 and PASI\ 90 responders (C 75% and
\90% reduction in PASI scores from baseline,
excellent to even better disease improvement,
respectively) and PASI 90 responders [1]. In a
separate analysis of the AMAGINE-2 and -3 tri-
als, a significant association was observed
between the PASI response level and achieve-
ment of DLQI 0/1, regardless of treatment arm.
More patients who achieved PASI 100 (complete
resolution of all disease) than PASI 90 to\100
also achieved DLQI 0/1 (83.5 vs. 64.3%) [19]. In
the previous phase II trial of brodalumab,
patients who achieved total skin clearance (PASI
100) reported greater HRQoL improvements
than those who were responders but were not
clear of disease (PASI 75 to\ 100) [20]. In
addition, more patients achieved a DLQI score
of 0 in the PASI 90 to\100 and PASI 100
groups compared with the PASI 75 to\90
group [21]. However, Abrouk et al. reported no
significant differences in DLQI between patients
achieving PASI 75 or PASI 90 in an analysis of
two ustekinumab clinical trials [22]. In a real-
world setting, improvements in PASI were
observed to be only weakly to moderately
associated with improvements in DLQI in
patients treated with ustekinumab [23]. Simi-
larly, data from the Danish National Registry
also suggested that the correlation between
PASI and DLQI is weak to moderate and varies
over time [24]. More research is needed to
confirm the correlation between PASI and DLQI
outcomes, especially outside of clinical trials.
Of the ten questions of the DLQI, eight offer
an NRR option that is scored as if the item had
no impact on patients, as a value of 0 is counted
for an NRR response. This can mean it is more
difficult for these patients to fulfil the DLQI[
10 criterion required to access biologic treat-
ment in some clinical guidelines. Female gen-
der, older age and more severe disease have
previously been associated with more NRRs
[10]. To address this, a new scoring formula
(DLQI-R) that adjusts the total score for the
number of NRRs has been proposed [11]. In our
analysis, the use of DLQI-R did not have a major
effect on the proportions of patients achieving
DLQI 0/1. For both treatments, the proportions
of patients achieving DLQI 0/1 was slightly
lower using DLQI-R than DLQI, which is the
opposite effect to that previously reported [10].
Most NRRs occurred in the sport, sexual diffi-
culties and working/studying items of the DLQI,
which is consistent with previous findings.
However, the proportions of reported NRRs
were lower in our analysis than previously
reported; for example, the domain with the
highest proportion of NRRs, sport, had 13.5%
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NNRs compared with 28.4% reported by Rencz
et al. [10]. The model was originally developed
based on data collected in cross-sectional anal-
yses and it is possible that patients enrolled in
clinical trials may be less likely to include ‘not
relevant’ as a response. If this is the case, the use
of DLQI-R may be less useful in a clinical trial
setting than when used to help guide treatment
decisions in clinical practice. Further validation
in clinical trials and clinical practice is required.
One possible limitation of this analysis is
that the original AMAGINE-2 and -3 studies
were conducted between 2012 and 2014.
Advances in treatment and greater disease
awareness among patients in the ensuing years
may have resulted in increased expectations of
complete skin clearance and improvements in
HRQoL. This may need to be taken into con-
sideration if comparing these DLQI results with
those of more recent studies. However, this
would not have impacted on the comparative
aspect of this trial.
In conclusion, brodalumab treatment pro-
vided significant improvement in self-reported
HRQoL in patients with moderate-to-severe
psoriasis compared with ustekinumab.
ACKNOWLEDGEMENTS
Funding. This analysis and manuscript
development, including Rapid Service Fee, was
funded by Leo Pharma A/S.
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published.
Medical Writing and Editorial Assis-
tance. Medical writing and editorial assistance
were provided by Andy Bond of Spirit Medical
Communications Group Ltd., funded by Leo
Pharma A/S.
Disclosures. Anne Sohrt and Jes Birger
Hansen are employees of Leo Pharma A/S. Jo
Lambert has received consultancy/speaker’s
honoraria from and/or participated in clinical
trials sponsored by Abbvie, Almirall, Amgen,
ArgenX, Celgene, Janssen, BIOCAD, LEO
Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB.
Lluı́s Puig has received consultancy/speaker’s
honoraria from and/or participated in clinical
trials sponsored by Abbvie, Almirall, Amgen,
Baxalta, Biogen, Boehringer Ingelheim, Cel-
gene, Gebro, Janssen, JS BIOCAD, LEO Pharma,
Lilly, Merck-Serono, MSD, Mylan, Novartis,
Pfizer, Regeneron, Roche, Sandoz, Samsung-
Bioepis, Sanofi, and UCB.
Compliance with Ethics Guidelines. An
institutional review board approved the study
protocol for each participating center. These
were: Research Review Board, Inc. Richmond
Hill, ON, Canada; Health Research Ethics Board
of Alberta Clinical Trials Committee, Edmon-
ton, AB, Canada; Eticka Komise Fakultni
nemocnice Kralovske Vinohrady, Praha, Czech
Republic; Eticka Komise Fakultni nemocnice
Kralovske Vinohrady, Brno, Czech Republic;
Eticka Komise Fakultni nemocnice, Praha Czech
Republic; Eticka Komise Fakultni nemocnice
Kralovske Vinohrady, Usti nad Labem, Czech
Republic; Eticka Komise Fakultni nemocnice,
Novy Jicin, Czech Republic; Eticka Komise
Fakultni nemocnice, Jihlava, Czech Republic;
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